Untitled

Зайцева, Н. И.; Gudasheva, T. A.; Briling, V. K.; Guzevatykh, L. S.; Ostrovskaya, R. U.; Воронина, Т. А.; Середенин, С. Б.

doi:10.1023/a:1005227325665

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Investigations of the stereoselectivity of the neuroleptic activity of tripeptoid analogs of neurotensin in the case of N-phenylacetylprolyltyrosine showed that (similar to the case of the dipeptide analog of sulpiride) this activity (Table 4) strongly depends on the configuration of tyrosine (only the diastereomers with L-Tyr are active) but not on that of proline (diastereomers with both L-and D-Pro are active) [16]. N-Caproyl-L-prolyl-L-tyrosine, the most active tripeptoid analog of neurotensin, was used to study the dependence of the neuroleptic activity on the nature of C-substitution [15].…”

Section: Design Of the Neurotensinergic Dipeptide Neuroleptic Drug DImentioning

confidence: 91%

Design of the Neurotensinergic Dipeptide Neuroleptic Drug Dilept

Gudasheva

Зайцева

2005

Pharm Chem J

Self Cite

View full text Add to dashboard Cite

An approach to the design of dipeptide neuroleptics free of extrapyramidal effects is described. Proceeding from an original hypothesis about the peptidergic mechanism of action of the atypical neuroleptic drug sulpiride and using the method of drug-based peptide synthesis, a peptide prototype of sulpiride -Pro-Tyr-NH 2 dipeptide -was obtained whose neuroleptic activity and the absence of cataleptogenic properties were revealed by tests on experimental animals. An analysis of the structures of known neuropeptides showed that the Pro-Tyr dipeptide sequence coincides with a Pro 10 -Tyr 11 fragment of the tridecapeptide neurotensin referred to in the literature as a neuropeptide with neuroleptic properties. Further design based on the obtained active dipeptide structure and the supposed bioactive b-rotational conformation of the neurotensin 8 -13 sequence led to a group of new potential atypical neuroleptics, N-acylprolyltyrosines. The structure of these tripeptoid analogs of neurotensin contains an N-acyl group imitating the Leu 13 side chain of neurotensin, which plays an important role in receptor binding. One of these compounds, N-caproyl-Lprolyl-L-tyrosine methyl ester, was named Dilept and chosen for more extensive pharmacological characterization as a potential antipsychotic agent. Preclinical investigations showed that Dilept is effective in doses 0.4 -4.0 mg/kg (i.p.) and retains activity upon peroral administration. The drug is nontoxic and does not induce extrapyramidal disorders even when administered in amounts 1000 times higher than the effective dose. 230 0091-150X/05/3905-0230

show abstract

Section: Design Of the Neurotensinergic Dipeptide Neuroleptic Drug DImentioning

confidence: 91%